人急性髓系白血病细胞OCI-AML-3
BLUEFBIO™ Product Sheet
|
细胞名称 |
人急性髓系白血病细胞OCI-AML-3 |
|
|
|
货物编码 |
BFN60810159 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研 3类 |
||
|
培养体系 |
90%DMEM+10%FBS+1%三抗 |
||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
简介 |
人急性髓系白血病细胞OCI-AML-3取自57岁男性外周血，悬浮培养。 |
||
|
注释 |
Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: LL-100 blood cancer cell line panel. Doubling time: 28 hours (PubMed=25984343); ~35-40 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: Deep quantitative phosphoproteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Derived from sampling site: Peripheral blood. |
||
|
基因突变 |
DNMT3A p.Arg882Cys (c.2644C>T) (PubMed=31160637; DSMZ). Heterozygous for NPM1 p.Trp288Cysfs*12 (c.860_863dupTCTG) (PubMed=16079892). |
||
|
HLA信息 |
/ |
||
|
STR信息 |
Amelogenin X CSF1PO 11,12 D3S1358 16 D5S818 11,13 D7S820 9,10 D8S1179 10,12 D13S317 8,13 D16S539 11,13 D18S51 12,18 D21S11 29,30 FGA 22 Penta D 12,13 Penta E 11,13 TH01 8,10 TPOX 8,11 vWA 17,18 |
||
|
参考文献 |
PubMed=30285677; DOI=10.1186/s12885-018-4840-5 Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P. Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. BMC Cancer 18:940-940(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
PubMed=31160637; DOI=10.1038/s41598-019-44491-x Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G. The LL-100 panel: 100 cell lines for blood cancer studies. Sci. Rep. 9:8218-8218(2019) |
||
